NIH scientists uncover brain circuitry behind face detection in primates

The FDA has granted fast track designation to Quince Therapeutics’ Phase III drug candidate EryDex to treat rare disease ataxia-telangiectasia. Credit: grandbrothers via Shutterstock. California-based

The on­ly clin­i­cal-stage an­ti­body-drug con­ju­gate in Sanofi’s pipeline has flunked a Phase III study, push­ing the French drug­mak­er to wind down the en­tire de­vel­op­ment pro­gram.